FORM 4
☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Darvish Nissim		 2. Issuer Name and Ticker or Trading Symbol

Chemomab Therapeutics Ltd. [ CMMB ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O CHEMOMAB THERAPEUTICS LTD., KIRYAT ATIDIM, BUILDING 7		 3. Date of Earliest Transaction (MM/DD/YYYY)

3/16/2023
(Street)

TEL AVIV, L3 6158002		 4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)        (State)        (Zip)
Rule 10b5-1(c) Transaction Indication
☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
American Depositary Shares         1200 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Option to Purchase American Depositary Shares (2)$1.62 3/16/2023  A   6857     (3)3/21/2033 American Depositary Shares (1)6857 $0 6857 D  
Option to Purchase American Depositary Shares (2)$3.53 3/7/2022  A   6820     (4)3/7/2032 American Depositary Shares (1)6820 $0 6820 D  
Option to Purchase American Depositary Shares (2)$27.26 4/19/2021  A   11884     (5)4/19/2031 American Depositary Shares (1)11884 $0 11884 D  
Option to Purchase American Depositary Shares (2)$0.8 10/28/2016  A   10123     (6)10/27/2017 American Depositary Shares (1)10123 $0 10123 D  
Explanation of Responses:
(1) Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
(2) No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
(3) These options were granted as per the annual grant of options to directors. These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.
(4) These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors.
(5) These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
(6) The options reported in this row have all vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Darvish Nissim
C/O CHEMOMAB THERAPEUTICS LTD.
KIRYAT ATIDIM, BUILDING 7
TEL AVIV, L3 6158002		X
Signatures
/s/ Matthew Rudolph, Esq., Attorney-in-Fact for Nissim Darvish3/23/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Anchiano Therapeutics (NASDAQ:ANCN)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Anchiano Therapeutics Charts.
Anchiano Therapeutics (NASDAQ:ANCN)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Anchiano Therapeutics Charts.